Selvita SA (SLV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Selvita SA (SLV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH248860D
  • |
  • Pages: 35
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Selvita SA (Selvita) is a drug discovery company that focuses on the research and development of cancer therapies. The company develops novel small molecule drugs, and markets them with partners from the pharmaceutical industry. Its products find application in the therapeutic areas of oncology, inflammation, leukemia, lymphoma, solid tumors and hematological malignancies. Selvita also offers services such as contract chemistry services, biology services, drug discovery services, computational chemistry, medicinal chemistry, analytical services, preclinical research, and quality assurance services. The company caters to pharmaceutical and biotechnology companies. It has presence in Poland, the US and the UK. Selvita is headquartered in Krakow, Poland.

Selvita SA (SLV)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Selvita SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Selvita SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Selvita SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Selvita SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Selvita SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Selvita SA, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Selvita Enters into Agreement with Leukemia & Lymphoma Society 10

Selvita Enters into Agreement with Nodthera 11

Selvita Enters into Agreement with University of California, San Francisco 12

Selvita Enters into Agreement with Merck 13

Selvita Enters into Development and Commercialization Agreement with Merck 14

Felicitex Therapeutics Enters into Co-Development Agreement with Selvita 15

Merck Serono Enters Into Co-Development Agreement With Selvita For Cancer Drugs 16

H3 Biomedicine Extends Agreement with Selvita 17

Licensing Agreements 18

Berlin-Chemie Enters into Licensing Agreement with Selvita 18

Merck Enters into Licensing Agreement with Selvita 19

Equity Offering 20

Selvita Raises USD40.3 Million in Public Offering of Shares 20

Selvita Raises USD0.1 Million in Private Placement of Shares 21

Selvita Raises USD8 Million in IPO 22

Selvita SA-Key Competitors 24

Selvita SA-Key Employees 25

Selvita SA-Locations And Subsidiaries 26

Head Office 26

Other Locations & Subsidiaries 26

Recent Developments 27

Financial Announcements 27

Sep 11, 2018: Selvita announces H1 2018 financial results 27

May 25, 2018: Selvita reports strong business growth in Q1 2018 28

Apr 04, 2018: Selvita shows a very strong, 60% business growth in 2017 29

Sep 15, 2017: Selvita Demonstrates Strong Revenue Growth in H1 2017 30

May 31, 2017: Selvita doubles the revenue in Q1 2017 vs. Q1 2016 31

Apr 20, 2017: Selvita Shows 19% Business Growth in 2016 32

Corporate Communications 33

Feb 06, 2018: Selvita Appoints Steffen Heeger, M.D., PhD as Chief Medical Officer 33

Product News 34

Feb 13, 2017: Selvita researchers publish MNK inhibitors review in Current Medicinal Chemistry 34

Appendix 35

Methodology 35

About GlobalData 35

Contact Us 35

Disclaimer 35

List of Figures

Selvita SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Selvita SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Selvita SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Selvita SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Selvita SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Selvita SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Selvita SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Selvita SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

List of Tables

Selvita SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Selvita SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Selvita SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Selvita SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Selvita SA, Deals By Therapy Area, 2012 to YTD 2018 8

Selvita SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Selvita Enters into Agreement with Leukemia & Lymphoma Society 10

Selvita Enters into Agreement with Nodthera 11

Selvita Enters into Agreement with University of California, San Francisco 12

Selvita Enters into Agreement with Merck 13

Selvita Enters into Development and Commercialization Agreement with Merck 14

Felicitex Therapeutics Enters into Co-Development Agreement with Selvita 15

Merck Serono Enters Into Co-Development Agreement With Selvita For Cancer Drugs 16

H3 Biomedicine Extends Agreement with Selvita 17

Berlin-Chemie Enters into Licensing Agreement with Selvita 18

Merck Enters into Licensing Agreement with Selvita 19

Selvita Raises USD40.3 Million in Public Offering of Shares 20

Selvita Raises USD0.1 Million in Private Placement of Shares 21

Selvita Raises USD8 Million in IPO 22

Selvita SA, Key Competitors 24

Selvita SA, Key Employees 25

Selvita SA, Other Locations 26

Selvita SA, Subsidiaries 26

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Selvita SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17743
Site License
USD 500 INR 35485
Corporate User License
USD 750 INR 53228

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com